Methyl Tertiary Butyl Ether ("MTBE")

This docket is one of the oldest active dockets on the JPML's pending list, and its current pending-action count of four reflects a litigation that has largely run its course through two and a half decades of case-specific resolutions rather than a single global settlement. MTBE claims are brought predominantly by public water suppliers and, in some cases, private well owners against gasoline refiners and additive manufacturers for the cost of testing, treating, and remediating groundwater contaminated by the additive leaking from underground storage tanks. There is no personal-injury component driving these claims — the exposure is to a resource (drinking water), and the damages are engineering and remediation costs, property diminution, and in some instances punitive exposure tied to knowledge of the additive's known migration risk.

For a funder, what remains active in this docket today looks less like inventory finance against a large plaintiff-firm book and more like single-matter or small-portfolio commercial litigation finance: a handful of water-provider plaintiffs with technical damages models built on contamination plume mapping and treatment-cost projections. That profile favors non-recourse commercial litigation finance sized to the specific claim rather than a firm-capital facility built around volume. Diligence on any remaining MTBE claim should center on the strength of the causation and damages record built up over the life of the MDL — this is not an early-stage docket where funders are pricing uncertainty from scratch; two decades of expert work, prior settlements with other refiners, and established remediation-cost methodologies already exist as comparables.

Because the injury theory here is environmental and economic rather than bodily, medical-lien considerations do not apply, and duration risk is now shaped more by the pace of remediation litigation and any remaining refiner-by-refiner settlement negotiations than by a centralized bellwether or settlement-fund calendar. A funder evaluating one of these claims today is effectively underwriting a mature commercial dispute, not a mass-tort inventory play. Criterica Capital's commercial litigation finance line is built for exactly this kind of claim-specific, economic-loss matter.

Criterica Intelligence also publishes a structural brief on this docket covering the procedural history and remaining exposure in more detail for firms evaluating whether to bring or fund a late-stage MTBE claim.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.